T1	CHEM 61 70	quitosano
#1	AnnotatorNotes T1	C0162969; Chitosan; Organic Chemical · Pharmacologic Substance
T2	CHEM 75 85	manzanilla
#2	AnnotatorNotes T2	C0439963; Chamomile extract; Organic Chemical; Pharmacologic Substance
T3	PROC 87 127	ensayo clínico, enmascarado y controlado
#3	AnnotatorNotes T3	C0150108; Blinded; Research Activity + C0681867; Controlled Study; Research Activity
T4	CHEM 245 254	quitosano
#4	AnnotatorNotes T4	C0162969; Chitosan; Organic Chemical · Pharmacologic Substance
T5	PROC 140 160	evaluar la seguridad
#5	AnnotatorNotes T5	C1705187; Safety Study; Research Activity
T6	ANAT 833 852	lugar de aplicación
#6	AnnotatorNotes T6	C0229986; Application site; Anatomical Structure
T7	CHEM 219 229	manzanilla
#7	AnnotatorNotes T7	C0439963; Chamomile extract; Organic Chemical; Pharmacologic Substance
T8	ANAT 262 266	piel
#8	AnnotatorNotes T8	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T9	ANAT 1075 1094	lugar de aplicación
#9	AnnotatorNotes T9	C0229986; Application site; Anatomical Structure
T10	PROC 301 395	ensayo clínico fase I, enmascarado, controlado, no aleatorizado, de dosis única, con controles
T11	DISO 819 852	eritema en el lugar de aplicación
T12	PROC 842 852	aplicación
#10	AnnotatorNotes T12	C0185125; Application procedure; Therapeutic or Preventive Procedure
T13	PROC 892 902	evaluación
#11	AnnotatorNotes T13	C1261322; Evaluation procedure; Health Care Activity
T14	DISO 985 992	eritema
#12	AnnotatorNotes T14	C0041834; Erythema; Disease or Syndrome
T15	DISO 994 1005	descamación
#13	AnnotatorNotes T15	C0237849; Peeling of skin; Finding
T16	DISO 1007 1012	ardor
#14	AnnotatorNotes T16	C0085624; Burning sensation; Sign or Symptom
T17	DISO 1014 1021	prurito
#15	AnnotatorNotes T17	C0033774; Pruritus; Sign or Symptom
T18	PROC 1084 1094	aplicación
#16	AnnotatorNotes T18	C0185125; Application procedure; Therapeutic or Preventive Procedure
T19	PROC 1144 1154	evaluación
#17	AnnotatorNotes T19	C1261322; Evaluation procedure; Health Care Activity
T20	CHEM 1223 1227	agua
#18	AnnotatorNotes T20	C0043047; water; Pharmacologic Substance · Inorganic Chemical
T21	CHEM 1302 1312	manzanilla
#19	AnnotatorNotes T21	C0439963; Chamomile extract; Organic Chemical; Pharmacologic Substance
T22	PROC 1544 1560	Ensayos Clínicos
#20	AnnotatorNotes T22	C0008976; Clinical Trials; Research Activity
T23	ANAT 402 406	piel
#21	AnnotatorNotes T23	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T24	DISO 510 520	irritación
#22	AnnotatorNotes T24	C0587867; Irritation symptom; Finding
T25	DISO 753 763	patologías
#23	AnnotatorNotes T25	C0677042; Pathology processes; Pathologic Function
T26	DISO 1024 1029	dolor
#24	AnnotatorNotes T26	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T27	ANAT 1061 1068	cutánea
#25	AnnotatorNotes T27	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T28	DISO 1357 1367	irritación
#26	AnnotatorNotes T28	C0587867; Irritation symptom; Finding
T29	ANAT 1395 1402	cutánea
#27	AnnotatorNotes T29	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T30	Route 180 186	tópica
#28	AnnotatorNotes T30	C1522168; Topical Route of Drug Administration; Functional Concept
T32	Dose 369 380	dosis única
T33	Age 659 668	26,3 años
T34	Neg_cue 749 752	sin
T37	Neg_cue 976 978	no
T39	Route 1331 1341	uso tópico
#29	AnnotatorNotes T39	C1522168; Topical Route of Drug Administration; Functional Concept
T40	Neg_cue 1343 1345	no
T41	Duration 1417 1431	cuatro semanas
T31	PHYS 523 534	hidratación
#30	AnnotatorNotes T31	C4520800; Hydration; Physiologic Function
T35	PHYS 1383 1394	hidratación
#31	AnnotatorNotes T35	C4520800; Hydration; Physiologic Function
T36	PHYS 1049 1060	hidratación
#32	AnnotatorNotes T36	C4520800; Hydration; Physiologic Function
T38	PHYS 1161 1176	función barrera
#33	AnnotatorNotes T38	C2246986; Skin barrier function; Organ or Tissue Function
T42	PHYS 1458 1473	función barrera
#34	AnnotatorNotes T42	C2246986; Skin barrier function; Organ or Tissue Function
T43	LIVB 270 283	participantes
#35	AnnotatorNotes T43	C4554048; Study Participant; Population Group
T44	LIVB 914 927	participantes
#36	AnnotatorNotes T44	C4554048; Study Participant; Population Group
T45	LIVB 776 788	participante
#37	AnnotatorNotes T45	C4554048; Study Participant; Population Group
T46	LIVB 627 640	participantes
#38	AnnotatorNotes T46	C4554048; Study Participant; Population Group
T47	LIVB 700 713	sexo femenino
#39	AnnotatorNotes T47	C0043210; Woman; Population Group
T48	LIVB 727 734	blancos
#40	AnnotatorNotes T48	C0043157; Caucasians; Population Group
A1	Assertion T25 Negated
A2	Assertion T14 Negated
A3	Assertion T15 Negated
A4	Assertion T16 Negated
A5	Assertion T17 Negated
A6	Assertion T26 Negated
A7	Assertion T28 Negated
A8	Status T25 History_of
R1	Combined_with Arg1:T1 Arg2:T2	
R2	Has_Route_or_Mode Arg1:T7 Arg2:T30	
R3	Combined_with Arg1:T7 Arg2:T4	
R4	Has_Route_or_Mode Arg1:T4 Arg2:T30	
R5	Experiences Arg1:T43 Arg2:T7	
T49	Quantifier_or_Qualifier 284 289	sanos
#41	AnnotatorNotes T49	C3898900; Healthy; Qualitative Concept
R6	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T49	
T50	CONC 552 569	tests de Wilcoxon
#42	AnnotatorNotes T50	C0242931; Wilcoxon Rank Test; Quantitative Concept
T51	CONC 572 587	Kruskall-Wallis
#43	AnnotatorNotes T51	C1708614; Kruskal-Wallis Test; Intellectual Product
R7	Has_Age Arg1:T46 Arg2:T33	
R8	Negation Arg1:T34 Arg2:T25	
R9	Experiences Arg1:T47 Arg2:T25	
R10	Experiences Arg1:T48 Arg2:T25	
T52	Observation 793 806	descontinuado
#44	AnnotatorNotes T52	C0424092; Withdrawn; Finding (?)
R11	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T52	
R12	Experiences Arg1:T45 Arg2:T11	
R13	Causes Arg1:T12 Arg2:T11	
R14	Location_of Arg1:T6 Arg2:T11	
T53	Neg_cue 866 868	no
T54	Observation 869 902	comparecer a la última evaluación
A9	Assertion T54 Negated
R15	Negation Arg1:T53 Arg2:T54	
R17	Experiences Arg1:T44 Arg2:T14	
R18	Experiences Arg1:T44 Arg2:T15	
R19	Experiences Arg1:T44 Arg2:T16	
R20	Experiences Arg1:T44 Arg2:T17	
R21	Experiences Arg1:T44 Arg2:T26	
R22	Negation Arg1:T37 Arg2:T14	
R23	Negation Arg1:T37 Arg2:T15	
R24	Negation Arg1:T37 Arg2:T16	
R25	Negation Arg1:T37 Arg2:T17	
R26	Negation Arg1:T37 Arg2:T26	
R27	Location_of Arg1:T27 Arg2:T36	
R28	Experiences Arg1:T44 Arg2:T36	
R29	Experiences Arg1:T44 Arg2:T18	
T55	Observation 1036 1068	mejora en la hidratación cutánea
R30	Experiences Arg1:T44 Arg2:T55	
R31	Location_of Arg1:T27 Arg2:T55	
T56	Observation 1182 1227	aumento de la pérdida transepidérmica de agua
R32	Has_Route_or_Mode Arg1:T21 Arg2:T39	
R33	Negation Arg1:T40 Arg2:T28	
R34	Location_of Arg1:T29 Arg2:T35	
T57	Observation 1370 1402	mejorando la hidratación cutánea
R35	Causes Arg1:T21 Arg2:T57	
R36	Has_Duration_or_Interval Arg1:T57 Arg2:T41	
R37	Before Arg1:T21 Arg2:T28	
T58	Neg_cue 349 351	no
T59	Quantifier_or_Qualifier 352 364	aleatorizado
A10	Assertion T59 Negated
R40	Negation Arg1:T58 Arg2:T59	
R41	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T59	
R42	Location_of Arg1:T6 Arg2:T12	
R43	Experiences Arg1:T45 Arg2:T12	
R16	Before Arg1:T11 Arg2:T52	
T60	Observation 932 954	finalizaron el estudio
#45	AnnotatorNotes T60	C2732579; Completion of clinical trial; Finding
R44	Location_of Arg1:T9 Arg2:T36	
R45	Location_of Arg1:T9 Arg2:T55	
T61	Observation 1444 1451	efectos
#46	AnnotatorNotes T61	C1518681; Outcome of Therapy; Finding (?)
#47	AnnotatorNotes T11	C0853700; Application site erythema; Pathologic Function
A11	Experiencer T43 Patient
A12	Experiencer T46 Patient
A13	Experiencer T47 Patient
A14	Experiencer T48 Patient
A15	Experiencer T45 Patient
A16	Experiencer T44 Patient
